<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406209</url>
  </required_header>
  <id_info>
    <org_study_id>NS2-02</org_study_id>
    <nct_id>NCT02406209</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis</brief_title>
  <official_title>A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-center, investigator masked, comparator controlled study. The
      purpose of this study is to determine the efficacy and safety of NS2 in patients with
      non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple
      doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%.

      Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a
      small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in Grade of anterior chamber cell count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of anterior chamber flare measured by slit lamp examination</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in Grade of Anterior chamber cell count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of limbal injection measured by slit lamp examination</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in limbal injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of hypopion measured by slit lamp examination</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in hypopion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of peripheral anterior synechiae measured by slit lamp examination</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in peripheral anterior synechiae</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of keratic precipitates measured by slit lamp examination</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in keratic precipitates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of posterior synechiae measured by slit lamp examination</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in posterior synechiae</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular pain score on the visual analog scale</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in ocular pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity measured by a standardized eye chart (ETDRS or Snellen)</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8</time_frame>
    <description>Change from baseline in visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment emergent adverse events as a measure of safety and tolerability</measure>
    <time_frame>Day 1, Day 4, Week 1, Week 2, Week 4, Week 8, Week 9</time_frame>
    <description>Change from baseline in the number of treatment emergent adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Non-infectious Anterior Uveitis</condition>
  <arm_group>
    <arm_group_label>NS2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NS2 ophthalmic drops (0.5%) in the affected eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NS2 and Pred Forte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pred Forte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate ophthalmic suspension (1%) in the affected eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NS2</intervention_name>
    <description>NS2 ophthalmic drops (0.5%)</description>
    <arm_group_label>NS2</arm_group_label>
    <arm_group_label>NS2 and Pred Forte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone acetate ophthalmic suspension (1%)</intervention_name>
    <arm_group_label>NS2 and Pred Forte</arm_group_label>
    <arm_group_label>Pred Forte</arm_group_label>
    <other_name>Pred Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-infectious anterior uveitis

          -  Grade 1 - Grade 3 anterior chamber cell count

          -  Subjects must have Intraocular pressure &lt;25 mmHg at baseline and may only administer a
             maximum of 1 topical medication to control Intraocular pressure in the study eye.

          -  Visual acuity ≥ 20/200 in the study eye

        Exclusion Criteria:

          -  Severe/serious ocular pathology

          -  Active intermediate or posterior uveitis.

          -  Previous anterior uveitis episode in the study eye within 4 weeks of Visit 1

          -  Oral corticosteroids within 14 days of Visit 1

          -  Intravitreal or sub-Tenon corticosteroid treatment in the study eye within the past 6
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.Stephen Foster, MD, FACS, FACR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye Research and Surgery Institution</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hull Eye Center</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates,PC</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center of Southern Connecticut</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518-3144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Eye Physicians &amp; Surgeons</name>
      <address>
        <city>Ayer</city>
        <state>Massachusetts</state>
        <zip>01940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye Research and Surgery Institution (MERSI)</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakland Ophthalmic Surgery</name>
      <address>
        <city>Birmingham</city>
        <state>Michigan</state>
        <zip>48009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifelong Vision Foundation</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Stanley Truhlsen Eye Institute</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Eye Research &amp; Surgery Institute</name>
      <address>
        <city>Palisades Park</city>
        <state>New Jersey</state>
        <zip>07650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitis</keyword>
  <keyword>acute uveitis</keyword>
  <keyword>anterior uveitis</keyword>
  <keyword>NS2</keyword>
  <keyword>Aldeyra</keyword>
  <keyword>prednisolone acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

